Tag Archives: Rock Springs Capital

← Older posts

Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early

The ability to detect early signs of cancer in a patient’s blood could improve prognoses by helping doctors treat the disease before symptoms arise. Freenome, one of the companies racing to commercialize the first such screening test, on Wednesday announced it raised $270 million—money it plans to accelerate a clinical study of an experimental screening […]

Posted in Boston blog main, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early

Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study. Many cancers grow silently, and once malignant cells are discovered a patient’s prognosis […]

Posted in Boston blog main, Boston top stories, National, National blog main, National top stories, San Diego blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test

Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx

Cancer treatment is increasingly moving toward targeted therapies based on the genetics of a patient’s tumor and Invitae is ensuring it gets its share of this growing market with a deal to acquire precision oncology startup ArcherDx. San Francisco-based Invitae announced Monday that it has agreed to pay $886 million for ArcherDx—$325 million in cash […]

Posted in Boulder/Denver blog main, Boulder/Denver top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx

Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic

Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised $102 million to move into clinical testing next year. The Series C round of […]

Posted in Boston, Boston blog main, Boston top stories, Europe blog main, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic

Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug

Spruce Biosciences has raised $88 million to advance clinical testing of a drug for a rare inherited endocrine disorder that can lead to a potentially life-threatening hormonal imbalance. San Francisco-based Spruce aims to treat a form of congenital adrenal hyperplasia (CAH), an inherited condition that leads to a deficiency in enzymes needed to produce certain […]

Posted in Detroit blog main, Detroit top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug

Mirum Pharmaceuticals Launches with $120M to Advance Liver Drugs

Serial entrepreneur Mike Grey is launching a biotech enterprise with $120 million in new funding to advance two investigational liver disease drugs—one of which he has worked to develop before. Called Mirum Pharmaceuticals, the startup is developing a compound, maralixibat, to treat Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), genetic liver disorders that […]

Posted in National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Mirum Pharmaceuticals Launches with $120M to Advance Liver Drugs

Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist

One day after the release of a Nature Medicine paper warning of the potential hazards of testing CRISPR-Cas9 gene editing in humans, Homology Medicines, a startup advancing a different genetic surgery technique, has just grabbed a big round of funding to make its own clinical push. Homology, of Bedford, MA, wrapped up an $83.5 million […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist

Google’s Venture Arm Leads $51.7M Investment in Spero Therapeutics

Despite the growing problem of drug-resistant bacteria, few new antibiotics have been developed in recent decades. Spero Therapeutics is trying to fill that gap by assembling a pipeline of antibiotic candidates, and it now has $51.7 million in new capital to finance clinical trials on some of them. GV, the venture arm of Google, led […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Google’s Venture Arm Leads $51.7M Investment in Spero Therapeutics

Biohaven Receives $80,000,000 New Round

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5e253804-c186-4329-8509-97ba1ad8d714 Date 11/2/2016 Company Name Biohaven Mailing Address 234 Church Street New Haven, CT 06510 USA Company Description Biohaven is a privately-held biopharmaceutical company with particular expertise in late stage clinical development and has portfolio of multiple late stage drug assets. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma […]

Posted in Boston, Boston VentureDeal VC | Tagged , , , , , , , , , , , , | Comments Off on Biohaven Receives $80,000,000 New Round

Mersana Therapeutics Receives $33,000,000 Series C Financing

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=83d86111-25c5-4221-8c34-704bdb0f14fe Date 6/16/2016 Company Name Mersana Therapeutics Mailing Address 840 Memorial Drive Cambridge, MA 02139 USA Company Description Mersana Therapeutics, Inc. (formerly Nanopharma Corp.) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs. Website http://www.mersana.com Transaction Type Venture Equity Transaction […]

Posted in Boston, Boston VentureDeal VC | Tagged , , , , , , , | Comments Off on Mersana Therapeutics Receives $33,000,000 Series C Financing← Older posts